Somatostatin pretreatment enhances growth hormone (GH) responsiveness to GH-releasing hormone: A potential new diagnostic approach to GH deficiency

Journal of Clinical Endocrinology and Metabolism

Volumn 81, Issue 7, 1996, Pages 2487-2494

  Tzanela, Marinella ^c   Guyda, Harvey ^a   Van Vliet, Guy ^b   Tannenbaum, Gloria S ^a,d  

^a MONTREAL CHILDREN S HOSPITAL   (Canada)

^b UNIVERSITY OF MONTREAL   (Canada)

^c RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^d UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; GROWTH HORMONE RELEASING FACTOR; SOMATOSTATIN;

ADOLESCENT; ARTICLE; BODY GROWTH; CHILD; CLINICAL ARTICLE; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FEMALE; GROWTH HORMONE DEFICIENCY; GROWTH HORMONE RELEASE; HUMAN; MALE; PRIORITY JOURNAL;

ADOLESCENT; ADULT; BLOOD GLUCOSE; BODY HEIGHT; CHILD; CHILD, PRESCHOOL; FEMALE; GROWTH HORMONE; GROWTH HORMONE-RELEASING HORMONE; HORMONES; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; OCTREOTIDE;

EID: 0029896735     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.81.7.2487     Document Type: Article

References (46)

1. Tannenbaum GS, Ling N. 1984 The interrelationship of growth hormone (GH)-releasing factor and somatostatin in generation of the ultradian rhythm of GH secretion. Endocrinology. 115:1952-1957.
2. Vance ML, Kaiser DL, Evans WS, et al. 1985 Pulsatile growth hormone secretion in normal man during a continuous 24-h infusion of human growth hormone releasing factor (1-40). J Clin Invest. 75:1584-1590.
3. Plotsky PM, Vale W. 1985 Patterns of growth hormone-releasing factor and somatostatin secretion into the hypophysial-portal circulation of the rat. Science. 230:461-463.
4. Tannenbaum GS, Painson J-C, Lengyel AMJ, Brazeau P. 1989 Paradoxical enhancement of pituitary growth hormone (GH) responsiveness to GH releasing factor in the face of high somatostatin tone. Endocrinology. 124:1380-1388.
5. Turner JP, Tannenbaum GS. 1995 In vivo evidence of a positive role for somatostatin to optimize pulsatile growth hormone secretion. Am J Physiol. 269:E683-E690.
6. Losa M, Müller OA, Sobieszczyk S, Von Werder K. 1985 Interaction between growth hormone releasing factor (GRF) and somatostatin analogue (SMS 201-995) in normal subjects. Clin Endocrinol. 23:715-720.
7. Kelijman M, Frohman LA. 1990 Impaired inhibitory effects of somatostatin on growth hormone (GH)-releasing hormone stimulation of GH secretion after short term infusion. J Clin Endocrinol Metab. 71:157-163.
8. Hindmarsh PC, Brain CE, Robinson ICAF, Matthews DR, Brook CGD. 1991 The interaction of growth hormone releasing hormone and somatostatin in the generation of a GH pulse in man. Clin Endocrinol. 35:353-360.
9. Rosenfeld RG, Albertsson-Wikland K, Cassorla F, et al. 1995 Diagnostic controversy: the diagnosis of childhood growth hormone deficiency revisited. J Clin Endocrinol Metab. 80:1532-1540.
10. Costin G, Kaufman FR, Brasel JA. 1989 Growth hormone secretory dynamics in subjects with normal stature. J Pediatr. 115:537-544.
11. Tassoni P, Cacciari E, Cau M, et al. 1990 Variability of growth hormone response to pharmacological and sleep tests performed twice in short children. J Clin Endocrinol Metab. 71:230-234.
12. Zadik Z, Chalew SA, Gilula Z, Kowarski AA. 1990 Reproducibility of growth hormone testing procedures: a comparison between 24-hour integrated concentration and pharmacological stimulation. J Clin Endocrinol Metab. 71:1127-1130.
13. Gelato MC, Malozowski S, Caruso-Nicoletti M, et al. 1986 Growth hormone (GH) responses to GH-releasing hormone during pubertal development in normal boys and girls: comparison to idiopathic short stature and GH deficiency. J Clin Endocrinol Metab. 63:174-179.
14. Butenandt O. 1989 Diagnostic value of growth hormone-releasing hormone tests in short children. Acta Paediatr Scand [Suppl]. 349:93-99.
15. Dickerman Z, Guyda H, Tannenbaum GS. 1993 Pretreatment with somatostatin analog SMS 201-995 potentiates growth hormone (GH) responsiveness to GH-releasing factor in short children. J Clin Endocrinol Metab. 77:652-657.
16. Valcavi R, Zini M. 1994 Octreotide administration, under particular temporal conditions, enhances the responses of growth hormone to growth hormone-releasing hormone in normal subjects. Clin Endocrinol. 40:379-382.
17. Tanner JM. 1962 Growth at Adolescence. Oxford: Blackwell Scientific Publications; p. 28.
18. Guyda HJ. 1975 Heterogeneity of hGH and prolactin secreted in vitro: immunoassay and radioreceptor assay correlations. J Clin Endocrinol Metab. 41:953-967.
19. Costigan DC, Guyda HJ, Posner BI. 1988 Free insulin like growth factor I (1GF-I) and IGF-II in human saliva. J Clin Endocrinol Metab. 66:1014-1018.
20. Juul A, Bang P, Hertel NT, et al. 1994 Serum insulin-like growth factor-I in 1030 healthy children, adolescents, and adults: relation to age, sex, stage of puberty, testicular size, and body mass index. J Clin Endocrinol Metab. 78:744-752.
21. Kraicer J, Cowan JS, Sheppard MS, Lussier B, Moor BC. 1986 Effect of somatostatin withdrawal and growth hormone (GH)-releasing factor on GH release in vitro: amount available for release after disinhibition. Endocrinology. 119:2047-2051.
22. Weiss J, Cronin MJ, Thorner MO. 1987 Periodic interactions of GH-releasing factor and somatostatin can augment GH release in vitro. Am J Physiol. 253:E508-E514.
23. Clayton RN, Bailey LC. 1987 Somatostatin partially reverses desensitization of somatotrophs induced by growth hormone-releasing factor. J Endocrinol. 112:69-76.
24. Soya H, Suzuki M. 1988 Somatostatin rapidly restores rat growth hormone (GH) release response attenuated by prior exposure to human GH-releasing factor in vitro. Endocrinology. 122:2492-2498.
25. Stachura ME. 1977 Interaction of somatostatin inhibition and dibutyryl cyclic AMP or potassium stimulation on growth hormone release from perifused rat pituitaries. Endocrinology. 101:1044-1053.
26. Reisine T, Axelrod J. 1983 Prolonged somatostatin pretreatment desensitizes somatostatin's inhibition of receptor-mediated release of adrenocorticotropin hormone and sensitizes adenylate cyclase. Endocrinology. 113:811-813.
27. Smith M, Yamamoto G, Vale W. 1984 Somatostatin desensitization in rat anterior pituitary cells. Mol Cell Endocrinol. 37:311-318.
28. 1 pituitary cells and does not reduce cellular responsiveness to somatostatin. J Biol Chem. 263:714-721.
29. 3 cells. Mol Pharmacol. 33:370-376.
30. Lamberts SWJ, Uitterlinden P, del Pozo E. 1987 SMS 201-995 induces a continuous decline in circulating growth hormone and somatomedin-C levels during therapy of acromegalic patients for over two years. J Clin Endocrinol Metab. 65:703-710.
31. Newman CB, Melmed S, Snyder PJ, et al. 1995 Safety and efficacy of long term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients a Clinical Research Center Study. J Clin Endocrinol Metab. 80:2768-2775.
32. Tannenbaum GS, Turner J, Guo F, Beaudet A. Homologous up-regulation of somatostatin receptor subtype SSTR2 expression in rat arcuate nucleus in vivo. Proc 25th Ann Meeting of the Society for Neuroscience, San Diego, CA, 1995, p. 1994. (Abstract A782.8).
33. 3 cells. Biochem Biophys Res Commun. 202:1738-1743.
34. Katakami H, Downs TR, Frohman LA. 1988 Inhibitory effect of hypothalamic medial preoptic area somatostatin on growth hormone-releasing factor in the rat. Endocrinology. 123:1103-1109.
35. Tannenbaum GS, McCarthy GF, Zeitler P, Beaudet A. 1990 Cysteamine-induced enhancement of growth hormone-releasing factor (GRF) immunore-activity in arcuate neurons: morphological evidence for putative somatostatin/GRF interactions within hypothalamus. Endocrinology. 127:2551-2560.
36. Daikoku S, Hisano S, Kawano H, et al. 1988 Ultrastructural evidence for neuronal regulation of growth hormone secretion. Neuroendocrinology. 47:405-415.
37. McCarthy GF, Beaudet A, Tannenbaum GS. 1992 Colocalization of somatostatin receptors and growth hormone-releasing factor immunoreactivity in neurons of the rat arcuate nucleus. Neuroendocrinology. 56:18-24.
38. Bertherat J, Dournaud P, Bérod A, et al. 1992 Growth hormone-releasing hormone-synthesizing neurons are a subpopulation of somatostatin receptor-labelled cells in the rat arcuate nucleus: a combined in situ hybridization and receptor light-microscopic radioautographic study. Neuroendocrinology. 56:25-31.
39. Shaw A, Stanhope R, Matthew D. 1992 Hazards of pharmacological tests of growth hormone secretion in childhood. Br Med J. 304:173-174.
40. Rose SR, Ross JL, Uriarte M, Barnes KM, Cassorla FG, Cutler, Jr, GB. 1988 The advantage of measuring stimulated as compared with spontaneous growth hormone levels in the diagnosis of growth hormone deficiency. New Engl J Med. 319:201-207.
41. Van Vliet G. 1988 Studies with growth hormone releasing factor in children: diagnostic and therapeutic implications. Acta Paediatr Jpn. 30:68-71.
42. Ezzat S, Ren S-G, Braunstein GD, Melmed S. 1991 Octreotide stimulates insulin-like growth factor binding protein-1 (IGFBP-1) levels in acromegaly. J Clin Endocrinol Metab. 73:441-443.
43. Flyvberg A, Jorgensen KD, Marshall SM, Orskov H. 1991 Inhibitory effect of octreotide on growth hormone-induced IGF-I generation and organ growth in hypophysectomized rats. Am J Physiol. 260:E568-E574.
44. Serri O, Brazeau P, Kachra Z, Posner B. 1992 Octreotide inhibits insulin-like growth factor-I hepatic gene expression in the hypophysectomized rat: evidence for a direct and indirect mechanism of action. Endocrinology. 130:1816-1821.
45. Ceda GP, Davis RG, Rosenfeld RG, Hoffman AR. 1987 The growth hormone (GH)-releasing hormone (GHRH)-GH-somatomedin axis: evidence for rapid inhibition of GHRH-elicited GH release by insulin-like growth factors I and II. Endocrinology. 120:1658-1662.
46. Greulich W, Pyle SI. 1959 Radiographic atlas of skeletal development of the hand and wrist. 2nd ed. Palo Alto: Stanford University Press.